Brief: Tiziana Life Sciences Announces Positive Results From Ozempic And Nasal Anti-CD3 Combination Study
30/10/2024 13:14
Oct 30 (Reuters) - Novo Nordisk A/S NOVOb.CO :
* TIZIANA LIFE SCIENCES ANNOUNCES POSITIVE RESULTS FROM
OZEMPIC
AND NASAL ANTI-CD3 COMBINATION STUDY
* TIZIANA LIFE SCIENCES LTD - COMBINATION OF NASAL ANTI-CD3
AND
SEMAGLUTIDE IMPROVES LIVER HOMEOSTASIS
* TIZIANA LIFE SCIENCES LTD - COMBINATION SIGNIFICANTLY
REDUCES
INFLAMMATION MARKERS IN OBESITY-RELATED DISORDERS
Source text: ID:nGNX6SW8ch
Further company coverage: NOVOb.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study